跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
TAVALISSE - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
TAVALISSE
Authorized
STANDARD
TAVALISSE
medison pharma canada inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
f85cd1665e308b1c
Company
medison pharma canada inc.
Type
Standard
Approval Details
Approval Id
f85cd1665e308b1c
Drug Approval Canada Name
TAVALISSE
Product Name
TAVALISSE
Status
Marketed
Status Date
2022-07-04
Original Market Date
2020-12-10
Din
02508060
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
20:28.16
Atc Original
B02BX09 FOSTAMATINIB
Atc Name
b 02 bx 09
Aig Number
0162598001
Company Name
medison pharma canada inc.
Company Address
400-154 University Avenue, Toronto, Ontario, Canada, M5H 3Y9
Active Ingredients
FOSTAMATINIB (FOSTAMATINIB DISODIUM)
150 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
f85cd1665e308b1c
Type
Standard
Back to Health Canada Approvals